Seminars in Nephrology
Volume 26, Issue 2 , Pages 95-104 , March 2006

Lupus Nephritis

  • Neerja Agrawal
    • ,
  • Lo-Ku Chiang
    • ,
  • Ian R. Rifkin

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Dr. Ian R. Rifkin, Renal Section, Department of Medicine, Boston University School of Medicine, EBRC 5th Floor, 650 Albany St, Boston, MA 02118.

References 

  1. Hochberg MC . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum . 1997;40:1725
  2. Cameron JS . Systemic lupus erythematosus . In:  Nielson EG ,  Couser WG editor. Immunologic Renal Disease . Philadelphia, PA: Lippincott-Raven; 2001;p. 1057–1104
  3. Cameron JS . Lupus nephritis . J Am Soc Nephrol . 1999;10:413–424
  4. Adu D , Williams DG , Taube D , et al.   Late onset systemic lupus erythematosus and lupus-like disease in patients with apparent idiopathic glomerulonephritis . QJM . 1983;52:471–487
  5. Wandstrat A , Wakeland E . The genetics of complex autoimmune diseases (Non-MHC susceptibility genes) . Nat Immunol . 2001;2:802–809
  6. Manderson AP , Botto M , Walport MJ . The role of complement in the development of systemic lupus erythematosus . Annu Rev Immunol . 2004;22:431–456
  7. Nath SK , Kilpatrick J , Harley JB . Genetics of human systemic lupus erythematosus (The emerging picture) . Curr Opin Immunol . 2004;16:794–800
  8. Salmon JE , Millard S , Schachter LA , et al.   Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans . J Clin Invest . 1996;97:1348–1354
  9. Karassa FB , Trikalinos TA , Ioannidis JP . The Fc gamma RIIIA-F158 allele is a risk factor for the development of lupus nephritis (A meta-analysis) . Kidney Int . 2003;63:1475–1482
  10. Prokunina L , Gunnarsson I , Sturfelt G , et al.   The systemic lupus erythematosus-associated PDCD1 polymorphism PD1.3A in lupus nephritis . Arthritis Rheum . 2004;50:327–328
  11. Parsa A , Lovett DH , Peden EA , et al.   Renin-angiotensin system gene polymorphisms predict the progression to renal insufficiency among Asians with lupus nephritis . Genes Immun . 2005;6:217–224
  12. Karassa FB , Trikalinos TA , Ioannidis JP . Role of the Fcgamma receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis (A meta-analysis) . Arthritis Rheum . 2002;46:1563–1571
  13. Reefman E , Dijstelbloem HM , Limburg PC , et al.   Fcgamma receptors in the initiation and progression of systemic lupus erythematosus . Immunol Cell Biol . 2003;81:382–389
  14. Jorgensen TN , Gubbels MR , Kotzin BL . New insights into disease pathogenesis from mouse lupus genetics . Curr Opin Immunol . 2004;16:787–793
  15. Bagavant H , Deshmukh US , Gaskin F , et al.   Lupus glomerulonephritis revisited 2004 (Autoimmunity and end-organ damage) . Scand J Immunol . 2004;60:52–63
  16. Lauwerys BR , Wakeland EK . Genetics of lupus nephritis . Lupus . 2005;14:2–12
  17. Barr RG , Seliger S , Appel GB , et al.   Prognosis in proliferative lupus nephritis (The role of socio-economic status and race/ethnicity) . Nephrol Dial Transplant . 2003;18:2039–2046
  18. Ward MM , Studenski S . Clinical manifestations of systemic lupus erythematosus . Identification of racial and socioeconomic influences. Arch Intern Med . 1990;150:849–853
  19. Grimaldi CM , Hill L , Xu X , et al.   Hormonal modulation of B cell development and repertoire selection . Mol Immunol . 2005;42:811–820
  20. Kotzin BL . Systemic lupus erythematosus . Cell . 1996;85:303–306
  21. Shlomchik MJ , Craft JE , Mamula MJ . From T to B and back again (Positive feedback in systemic autoimmune disease) . Nat Rev Immunol . 2001;1:147–153
  22. Plotz PH . The autoantibody repertoire (Searching for order) . Nat Rev Immunol . 2003;3:73–78
  23. Arbuckle MR , McClain MT , Rubertone MV , et al.   Development of autoantibodies before the clinical onset of systemic lupus erythematosus . N Engl J Med . 2003;349:1526–1533
  24. Salvador JM , Hollander MC , Nguyen AT , et al.   Mice lacking the p53-effector gene Gadd45a develop a lupus-like syndrome . Immunity . 2002;16:499–508
  25. Majeti R , Xu Z , Parslow TG , et al.   An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity . Cell . 2000;103:1059–1070
  26. Nishimura H , Nose M , Hiai H , et al.   Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor . Immunity . 1999;11:141–151
  27. Bolland S , Ravetch JV . Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis . Immunity . 2000;13:277–285
  28. Mackay F , Woodcock SA , Lawton P , et al.   Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations . J Exp Med . 1999;190:1697–1710
  29. Cohen PL , Eisenberg RA . Lpr and gld (Single gene models of systemic autoimmunity and lymphoproliferative disease) . Annu Rev Immunol . 1991;9:243–269
  30. Botto M , Dell’Agnola C , Bygrave AE , et al.   Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies . Nat Genet . 1998;19:56–59
  31. Bickerstaff MCM , Botto M , Hutchinson WL , et al.   Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity . Nat Med . 1999;5:694–697
  32. Lu Q , Lemke G . Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family . Science . 2001;293:306–311
  33. Napirei M , Karsunky H , Zevnik B , et al.   Features of systemic lupus erythematosus in Dnase1-deficient mice . Nat Genet . 2000;25:177–181
  34. Hanayama R , Tanaka M , Miyasaka K , et al.   Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice . Science . 2004;304:1147–1150
  35. Amoura Z , Piette JC , Chabre H , et al.   Circulating plasma levels of nucleosomes in patients with systemic lupus erythematosus (Correlation with serum antinucleosome antibody titers and absence of clear association with disease activity) . Arthritis Rheum . 1997;40:2217–2225
  36. Rumore PM , Steinman CR . Endogenous circulating DNA in systemic lupus erythematosus. Occurrence as multimeric complexes bound to histone . J Clin Invest . 1990;86:69–74
  37. Savill J , Dransfield I , Gregory C , et al.   A blast from the past (Clearance of apoptotic cells regulates immune responses) . Nat Rev Immunol . 2002;2:965–975
  38. Tan EM . Antinuclear antibodies (Diagnostic markers for autoimmune diseases and probes for cell biology) . Adv Immunol . 1989;44:93–151
  39. Rahman MAA , Isenberg DA . Autoantibodies and lupus nephritis . In:  Lewis EJ ,  Schwartz MM ,  Korbet SM editor. Lupus Nephritis . Oxford: Oxford University Press; 1999;p. 1–21
  40. Alba P , Bento L , Cuadrado MJ , et al.   Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant (Significant factors associated with lupus nephritis) . Ann Rheum Dis . 2003;62:556–560
  41. Mostoslavsky G , Fischel R , Yachimovich N , et al.   Lupus anti-DNA autoantibodies cross-react with a glomerular structural protein (A case for tissue injury by molecular mimicry) . Eur J Immunol . 2001;31:1221–1227
  42. Zhao Z , Weinstein E , Tuzova M , et al.   Cross-reactivity of human lupus anti-DNA antibodies with alpha-actinin and nephritogenic potential . Arthritis Rheum . 2005;52:522–530
  43. Yanase K , Smith RM , Puccetti A , et al.   Receptor-mediated cellular entry of nuclear localizing anti-DNA antibodies via myosin 1 . J Clin Invest . 1997;100:25–31
  44. Liang Z , Xie C , Chen C , et al.   Pathogenic profiles and molecular signatures of antinuclear autoantibodies rescued from NZM2410 lupus mice . J Exp Med . 2004;199:381–398
  45. Brentjens JR , Sepulveda M , Baliah T , et al.   Interstitial immune complex nephritis in patients with systemic lupus erythematosus . Kidney Int . 1975;7:342–350
  46. Appel GB , Pirani CL , D’Agati V . Renal vascular complications of systemic lupus erythematosus . J Am Soc Nephrol . 1994;4:1499–1515
  47. Clynes R , Dumitru C , Ravetch JV . Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis . Science . 1998;279:1052–1054
  48. Matsumoto K , Watanabe N , Akikusa B , et al.   Fc receptor-independent development of autoimmune glomerulonephritis in lupus-prone MRL/lpr mice . Arthritis Rheum . 2003;48:486–494
  49. Trouw LA , Groeneveld TW , Seelen MA , et al.   Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes . J Clin Invest . 2004;114:679–688
  50. Waldman M , Madaio MP . Pathogenic autoantibodies in lupus nephritis . Lupus . 2005;14:19–24
  51. Kramers C , Hylkema MN , van Bruggen MC , et al.   Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo . J Clin Invest . 1994;94:568–577
  52. Alexopoulos E , Seron D , Hartley RB , et al.   Lupus nephritis (Correlation of interstitial cells with glomerular function) . Kidney Int . 1990;37:100–109
  53. Park MH , D’Agati V , Appel GB , et al.   Tubulointerstitial disease in lupus nephritis (Relationship to immune deposits, interstitial inflammation, glomerular changes, renal function, and prognosis) . Nephron . 1986;44:309–319
  54. Moroni G , Ventura D , Riva P , et al.   Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis . Am J Kidney Dis . 2004;43:28–36
  55. Ronnblom L , Alm GV . An etiopathogenic role for the type I IFN system in SLE . Trends Immunol . 2001;22:427–431
  56. Pascual V , Banchereau J , Palucka AK . The central role of dendritic cells and interferon-alpha in SLE . Curr Opin Rheumatol . 2003;15:548–556
  57. Baechler EC , Gregersen PK , Behrens TW . The emerging role of interferon in human systemic lupus erythematosus . Curr Opin Immunol . 2004;16:801–807
  58. Santiago-Raber ML , Baccala R , Haraldsson KM , et al.   Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice . J Exp Med . 2003;197:777–788
  59. Mathian A , Weinberg A , Gallegos M , et al.   IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice . J Immunol . 2005;174:2499–2506
  60. Hron JD , Peng SL . Type I IFN protects against murine lupus . J Immunol . 2004;173:2134–2142
  61. Gyorkey F , Min KW , Sincovics JG , et al.   Systemic lupus erythematosus and myxovirus . N Engl J Med . 1969;280:333
  62. Bloodworth JM , Shelp WD . Endothelial cytoplasmic inclusions . Arch Pathol . 1970;90:252–258
  63. Rich SA , Reilly AA . Evidence that the interferon-induced Daudi cell human lupus inclusions are de novo synthesized complexes of ribonucleoprotein and membrane . J Biol Chem . 1989;264:3529–3537
  64. Rich SA . Human lupus inclusions and interferon . Science . 1981;213:772–775
  65. Peterson KS , Huang JF , Zhu J , et al.   Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli . J Clin Invest . 2004;113:1722–1733
  66. Baechler EC , Batliwalla FM , Karypis G , et al.   Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus . Proc Natl Acad Sci U S A . 2003;100:2610–2615
  67. Kirou KA , Lee C , George S , et al.   Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease . Arthritis Rheum . 2005;52:1491–1503
  68. Vallin H , Perers A , Alm GV , et al.   Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus . J Immunol . 1999;163:6306–6313
  69. Ronnblom L , Alm GV . A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus . J Exp Med . 2001;194:F59–F63
  70. Suzuki K , Mori A , Ishii KJ , et al.   Activation of target-tissue immune-recognition molecules by double-stranded polynucleotides . Proc Natl Acad Sci U S A . 1999;96:2285–2290
  71. Zhu FG , Reich CF , Pisetsky DS . Effect of cytofectins on the immune response of murine macrophages to mammalian DNA . Immunology . 2003;109:255–262
  72. Leadbetter EA , Rifkin IR , Hohlbaum AM , et al.   Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors . Nature . 2002;416:603–607
  73. Boule MW , Broughton C , Mackay F , et al.   Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes . J Exp Med . 2004;199:1631–1640
  74. Yasuda K , Yu P , Kirschning CJ , et al.   Endosomal translocation of vertebrate DNA activates dendritic cells via TLR9-dependent and -independent pathways . J Immunol . 2005;174:6129–6136
  75. Means TK , Latz E , Hayashi F , et al.   Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9 . J Clin Invest . 2005;115:407–417
  76. Hemmi H , Takeuchi O , Kawai T , et al.   A Toll-like receptor recognizes bacterial DNA . Nature . 2000;408:740–745
  77. Heil F , Hemmi H , Hochrein H , et al.   Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8 . Science . 2004;303:1526–1529
  78. Diebold SS , Kaisho T , Hemmi H , et al.   Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA . Science . 2004;303:1529–1531
  79. Anders HJ , Banas B , Schlondorff D . Signaling danger (Toll-like receptors and their potential roles in kidney disease) . J Am Soc Nephrol . 2004;15:854–867
  80. Illei GG , Tackey E , Lapteva L , et al.   Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability . Arthritis Rheum . 2004;50:1709–1720
  81. Illei GG , Tackey E , Lapteva L , et al.   Biomarkers in systemic lupus erythematosus (II. Markers of disease activity) . Arthritis Rheum . 2004;50:2048–2065
  82. Churg J , Bernstein J , Glassock RJ . In: Renal disease (Classification and atlas of glomerular diseases) . ed 2. Tokyo: Igaku-Shoin; 1995;p. 151–179
  83. Weening JJ , D’Agati VD , Schwartz MM , et al.   The classification of glomerulonephritis in systemic lupus erythematosus revisited . J Am Soc Nephrol . 2004;15:241–250
  84. Glassock RJ . Reclassification of lupus glomerulonephritis (Back to the future) . J Am Soc Nephrol . 2004;15:501–503
  85. Austin HA , Muenz LR , Joyce KM , et al.   Diffuse proliferative lupus nephritis (Identification of specific pathologic features affecting renal outcome) . Kidney Int . 1984;25:689–695
  86. Schwartz MM , Lan SP , Bernstein J , et al.  Lupus Nephritis Collaborative Study Group   Irreproducibility of the activity and chronicity indices limits their utility in the management of lupus nephritis . Am J Kidney Dis . 1993;21:374–377
  87. Appel GB , Radhakrishnan J , D’Agati V . Secondary glomerular disease . In:  Brenner BM editors. The Kidney . ed 7. Philadelphia, PA: Saunders; 2004;p. 1381–1481
  88. Rifkin IR , Salant DJ . Immune-mediated glomerulopathies . In:  Humes HD editors. Kelley’s Textbook of Internal Medicine . ed 4. Philadelphia, PA: Lippincott, Williams, and Wilkins; 2000;p. 1191–1207
  89. Appel GB . Renal vascular involvement in SLE . In:  Lewis EJ ,  Schwartz MM ,  Korbet SM editor. Lupus Nephritis . Oxford: Oxford University Press; 1999;p. 241–261
  90. Singh AK , Ucci A , Madias NE . Predominant tubulointerstitial lupus nephritis . Am J Kidney Dis . 1996;27:273–278
  91. Esdaile JM , Joseph L , MacKenzie T , et al.   The benefit of early treatment with immunosuppressive agents in lupus nephritis . J Rheumatol . 1994;21:2046–2051
  92. Pollak VE , Pirani CL , Schwartz FD . The natural history of the renal manifestations of systemic lupus erythematosus. 1964 . J Am Soc Nephrol . 1997;8:1189–1198
  93. Schwartz MM , Kawala KS , Corwin H , et al.   The prognosis of segmental glomerulonephritis in systemic lupus erythematosus . Kidney Int . 1987;32:274–279
  94. Appel GB , Cohen DJ , Pirani CL , et al.   Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization . Am J Med . 1987;83:877–885
  95. Houssiau FA . Management of lupus nephritis (An update) . J Am Soc Nephrol . 2004;15:2694–2704
  96. Korbet SM , Lewis EJ , Schwartz MM , et al.  Lupus Nephritis Collaborative Study Group   Factors predictive of outcome in severe lupus nephritis . Am J Kidney Dis . 2000;35:904–914
  97. Houssiau FA , Vasconcelos C , D’Cruz D , et al.   Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis (Lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial) . Arthritis Rheum . 2004;50:3934–3940
  98. Moroni G , Quaglini S , Maccario M , et al.   “Nephritic flares” are predictors of bad long-term renal outcome in lupus nephritis . Kidney Int . 1996;50:2047–2053
  99. Mosca M , Bencivelli W , Neri R , et al.   Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis . Kidney Int . 2002;61:1502–1509
  100. Chan TM , Li FK , Tang CS , et al.  Hong Kong-Guangzhou Nephrology Study Group   Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis . N Engl J Med . 2000;343:1156–1162
  101. Contreras G , Pardo V , Leclercq B , et al.   Sequential therapies for proliferative lupus nephritis . N Engl J Med . 2004;350:971–980
  102. Petri M , Bockenstedt L , Colman J , et al.   Serial assessment of glomerular filtration rate in lupus nephropathy . Kidney Int . 1988;34:832–839
  103. Chagnac A , Kiberd BA , Farinas MC , et al.   Outcome of the acute glomerular injury in proliferative lupus nephritis . J Clin Invest . 1989;84:922–930
  104. Harvey AM , Shulman LE , Tumulty PA , et al.   Systemic lupus erythematosus (Review of the literature and clinical analysis of 138 cases) . Medicine . 1954;33:291–437
  105. Pollak VE , Pirani CL , Schwartz FD . The natural history of the renal manifestations of systemic lupus erythematosus . J Lab Clin Med . 1964;63:537–550
  106. Cathcart ES , Idelson BA , Scheinberg MA , et al.   Beneficial effects of methylprednisolone “pulse” therapy in diffuse proliferative lupus nephritis . Lancet . 1976;1:163–166
  107. Lewis EJ . The natural history and treatment of lupus nephritis . In:  Lewis EJ ,  Schwartz MM ,  Korbet SM editor. Lupus Nephritis . Oxford: Oxford University Press; 1999;p. 185–240
  108. Boumpas DT , Austin HA , Vaughn EM , et al.   Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis . Lancet . 1992;340:741–745
  109. Flanc RS , Roberts MA , Strippoli GF , et al.   Treatment of diffuse proliferative lupus nephritis (A meta-analysis of randomized controlled trials) . Am J Kidney Dis . 2004;43:197–208
  110. Austin HA , Klippel JH , Balow JE , et al.   Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs . N Engl J Med . 1986;314:614–619
  111. Steinberg AD , Steinberg SC . Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only . Arthritis Rheum . 1991;34:945–950
  112. Houssiau FA , Vasconcelos C , D’Cruz D , et al.   Immunosuppressive therapy in lupus nephritis (The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide) . Arthritis Rheum . 2002;46:2121–2131
  113. Chan TM , Tse KC , Tang CS , et al.   Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine . Lupus . 2005;14:265–272
  114. Appel GB , Ginzler EM , Radhakrishnan J , et al.   Multicenter controlled trial of mycophenolate mofetil (MMF) as induction therapy for severe lupus nephritis (LN) . J Am Soc Nephrol . 2003;14:38A; (abstr)
  115. Allison AC , Eugui EM . Mycophenolate mofetil and its mechanisms of action . Immunopharmacology . 2000;47:85–118
  116. Rose BD , Schur PH , Falk RJ , et al.   Treatment of lupus nephritis . In:  Rose BD ,  Rush J editor. UpToDate Online (vol 13.2) . 2005; Wellesley, MA, Available at: http://www.uptodateonline.com. Accessed July 7, 2005
  117. Goldblatt F , Isenberg DA . New therapies for systemic lupus erythematosus . Clin Exp Immunol . 2005;140:205–212
  118. Mackay F , Schneider P , Rennert P , et al.   BAFF AND APRIL (A tutorial on B cell survival) . Annu Rev Immunol . 2003;21:231–264
  119. Alarcon-Segovia D , Tumlin JA , Furie RA , et al.   LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus (Results from a randomized, double-blind, placebo-controlled study) . Arthritis Rheum . 2003;48:442–454
  120. Kremer JM , Westhovens R , Leon M , et al.   Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig . N Engl J Med . 2003;349:1907–1915
  121. Silverman GJ . Anti-CD20 therapy in systemic lupus erythematosus (A step closer to the clinic) . Arthritis Rheum . 2005;52:371–377
  122. van Vollenhoven RF , Gunnarsson I , Welin-Henriksson E , et al.   Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone . Scand J Rheumatol . 2004;33:423–427
  123. Sfikakis PP , Boletis JN , Lionaki S , et al.   Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand (An open-label trial) . Arthritis Rheum . 2005;52:501–513
  124. Chan OT , Madaio MP , Shlomchik MJ . The central and multiple roles of B cells in lupus pathogenesis . Immunol Rev . 1999;169:107–121
  125. Balow JE , Austin HA . Therapy of membranous nephropathy in systemic lupus erythematosus . Semin Nephrol . 2003;23:386–391
  126. Austin HA , Illei GG . Membranous lupus nephritis . Lupus . 2005;14:65–71
  127. Nikpour M , Urowitz MB , Gladman DD . Premature atherosclerosis in systemic lupus erythematosus . Rheum Dis Clin North Am . 2005;31:329–354
  128. Schiffenbauer J , Hahn B , Weisman MH , et al.   Biomarkers, surrogate markers, and design of clinical trials of new therapies for systemic lupus erythematosus . Arthritis Rheum . 2004;50:2415–2422

 Supported by grants from the National Institutes of Health (DK02597 and AR050256), the National Kidney Foundation, and the Lupus Research Institute (I.R.R.).

PII: S0270-9295(05)00183-X

doi: 10.1016/j.semnephrol.2005.09.002

Seminars in Nephrology
Volume 26, Issue 2 , Pages 95-104 , March 2006

Article Tools